# US 2020/0369730 A1 · Hepatitis b nanoparticle-based vaccine for influenza virus

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0369730 A1
- Document ID: US20200369730A1
- Status: Published application
- Kind: A1
- Application number: 16/635,240
- Filed: 2018-08-02
- Published: 2020-11-26
- Earliest claimed: 2017-08-02
- Assignees: The USA, as represented by the Secretary, Dept. of Health and Human Services
- Applicants: The USA, AS Represented By the Secretary, Dept. of Health and Human Services
- Inventors: Audray K. HARRIS; Dustin M. MCCRAW
- Web page: https://patentgrep.com/patent/US20200369730A1

## CPC

- A61K 39/12: Viral antigens
- C07K 14/11: Orthomyxoviridae, e.g. influenza virus
- A61K 39/145: Orthomyxoviridae, e.g. influenza virus
- A61P 31/16: for influenza or rhinoviruses
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 2730/10123: Virus like particles [VLP]
- C12N 2730/10144: Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- C12N 2760/16134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2760/16234: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Fusion proteins comprising one or more portions of hepatitis virus core antigen (HBcAg) fused to immunogenic portions of influenza virus hemagglutinin (HA) protein, and nanoparticles (virus-like particles) formed from such proteins, nucleic acid molecules encoding such proteins, methods of making such nanoparticles, methods of using the disclosed nanoparticles to vaccinate an individual against influenza virus, and antibodies elicited by vaccination of a mammal with the disclosed nanoparticles.

## Claims

### Claim 1

A fusion protein selected from the group consisting of:
a) a first fusion protein comprising an immunogenic peptide from helix A from the stem region of an influenza hemagglutinin (HA) protein, joined to the carboxyl-terminal end of the α3 helix from a hepatitis B core antigen (HBcAg); and,
b) a second fusion protein comprising an immunogenic peptide from helix A from the stem region of an influenza hemagglutinin (HA) protein, joined to the amino-terminal end of the α4 helix from a hepatitis B core antigen (HBcAg).

### Claim 2 (depends on 1)

The fusion protein of claim 1, wherein the first fusion protein forms a virus-like particle (VLP) when combined with a HAcAg-C protein, or wherein the second fusion protein forms a virus-like particle (VLP) when combined with a HAcAG-N protein.

### Claim 3 (depends on 1)

The fusion protein of claim 1, wherein the immunogenic peptide of the first fusion protein is joined to the carboxyl-terminal end of a HBcAg coreN domain.

### Claim 4 (depends on 1)

The fusion protein of claim 1, wherein the immunogenic peptide of the second fusion protein is joined to the amino-terminal end of a HBcAg core C domain.

### Claim 5 (depends on 1)

The fusion protein of claim 1, wherein one end of the immunogenic peptide is joined to the carboxyl-terminal end of the HBcAg α3 helix, wherein the other end of the helix A immunogenic peptide is joined to the amino-terminal end of the HBcAg α4 helix, and wherein the fusion protein forms a VLP that displays the influenza HA helix A on its surface.

### Claim 6 (depends on 1)

The fusion protein of claim 1, wherein the fusion protein comprises:
a) an immunogenic peptide from helix A in the stem region of an influenza hemagglutinin protein;
b) a first amino acid sequence comprising at least 30, at least 40, at least 50, or at least 60 contiguous amino residues from the polypeptide sequence immediately upstream of the HBcAg c/e1 loop sequence, wherein the first amino acid sequence comprises an HBcAg α3 helix sequence; and,
c) a second amino acid sequence comprising at least 50, at least 60, or at least 70 contiguous amino acid residues from the polypeptide sequence immediately downstream of the HBcAg c/e1 loop sequence, wherein the second amino acid sequence comprises an HBcAg α4 helix sequence;
wherein one end of the immunogenic peptide is joined to the carboxy-terminal end of the first amino acid sequence, and the other end of the immunogenic peptide is joined to the amino-terminal end of the second amino acid sequence; and, the fusion protein self-assembles into a VLP that displays the influenza HA helix A on its surface.

### Claim 7 (depends on 1)

The fusion protein of claim 1, wherein the fusion protein comprises:
a) an immunogenic peptide from helix A in the stem region of an influenza hemagglutinin (HA) protein;
b) a HBcAg coreN domain; and,
c) a HBcAg coreC domain;
wherein
one end of the immunogenic peptide is joined to the carboxy-terminal end of the coreN domain;
the other end of the immunogenic peptide is joined to the amino-terminal end of the coreC domain; and,
the fusion protein self-assembles into a VLP that displays the influenza HA helix A on its surface.

### Claim 8 (depends on 1)

The fusion protein of claim 1, wherein the fusion protein comprises the amino acid sequence of a HBcAg, and wherein the helix A immunogenic peptide is inserted into, or replaces, the c/e1 loop.

### Claim 9 (depends on 1)

A kit comprising the fusion protein of claim 1.

### Claim 10 (depends on 1)

A virus like particle (VLP) or nanoparticle comprising the fusion protein of claim 1.

### Claim 11 (depends on 10)

A vaccine composition comprising the VLP or nanoparticle of claim 10.

### Claim 12

(canceled)

### Claim 13 (depends on 10)

A method of eliciting an immune response against influenza virus in an individual, comprising administering to the individual the VLP or nanoparticle of claim 10.

### Claim 14

(canceled)

### Claim 15

(canceled)

### Claim 16

A nucleic acid molecule encoding a fusion protein selected from the group consisting of:
a) a first fusion protein comprising an immunogenic peptide from helix A from the stem region of an influenza hemagglutinin (HA) protein, joined to the carboxyl-terminal end of the α3 helix from a hepatitis B core antigen (HBcAg); and,
b) a second fusion protein comprising an immunogenic peptide from helix A from the stem region of an influenza hemagglutinin (HA) protein, joined to the amino-terminal end of the α4 helix from a hepatitis B core antigen (HBcAg).

### Claim 17 (depends on 16)

The nucleic acid molecule of claim 16, wherein the first fusion protein forms a virus-like particle (VLP) when combined with a HAcAg-C protein, or wherein the second fusion protein forms a virus-like particle (VLP) when combined with a HAcAG-N protein.

### Claim 18 (depends on 16)

The nucleic acid molecule of claim 16, wherein the immunogenic peptide of the first fusion protein is joined to the carboxyl-terminal end of a HBcAg coreN domain.

### Claim 19 (depends on 16)

The nucleic acid molecule of claim 16, wherein the immunogenic peptide of the second fusion protein is joined to the amino-terminal end of a HBcAg core C domain.

### Claim 20 (depends on 16)

The nucleic acid molecule of claim 16, wherein one end of the immunogenic peptide is joined to the carboxyl-terminal end of the HBcAg α3 helix, wherein the other end of the helix A immunogenic peptide is joined to the amino-terminal end of the HBcAg α4 helix, and wherein the fusion protein forms a VLP that displays the influenza HA helix A on its surface.

### Claim 21 (depends on 16)

The nucleic acid molecule of claim 16, wherein the fusion protein comprises:
a) an immunogenic peptide from helix A in the stem region of an influenza hemagglutinin protein;
b) a first amino acid sequence comprising at least 30, at least 40, at least 50, or at least 60 contiguous amino residues from the polypeptide sequence immediately upstream of the HBcAg c/e1 loop sequence, wherein the first amino acid sequence comprises an HBcAg α3 helix sequence; and,
c) a second amino acid sequence comprising at least 50, at least 60, or at least 70 contiguous amino acid residues from the polypeptide sequence immediately downstream of the HBcAg c/e1 loop sequence, wherein the second amino acid sequence comprises an HBcAg α4 helix sequence;
wherein one end of the immunogenic peptide is joined to the carboxy-terminal end of the first amino acid sequence, and the other end of the immunogenic peptide is joined to the amino-terminal end of the second amino acid sequence; and, the fusion protein self-assembles into a VLP that displays the influenza HA helix A on its surface.

### Claim 22 (depends on 16)

The nucleic acid molecule of claim 16, wherein the fusion protein comprises:
a) an immunogenic peptide from helix A in the stem region of an influenza hemagglutinin (HA) protein;
b) a HBcAg coreN domain; and,
c) a HBcAg coreC domain;
wherein
one end of the immunogenic peptide is joined to the carboxy-terminal end of the coreN domain;
the other end of the immunogenic peptide is joined to the amino-terminal end of the coreC domain; and,
the fusion protein self-assembles into a VLP that displays the influenza HA helix A on its surface.

### Claim 23 (depends on 16)

The nucleic acid molecule of claim 16, wherein the fusion protein comprises the amino acid sequence of a HBcAg, and wherein the helix A immunogenic peptide is inserted into, or replaces, the c/e1 loop.
